• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now

    10/4/23 7:00:00 AM ET
    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGBA alert in real time by email

    MIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 63rd Emerging Growth Conference on October 5th, 2023.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    For updates, follow us on Twitter

    Day 2

    October 5, 2023

    9:00

    Virtual Lobby opens. 

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    9:40 - 10:10

    Theriva Biologics (NYSE:TOVX)

    Steven A. Shallcross, CEO / CFO

    10:15 - 10:45

    Bioxytran, Inc. (OTCQB:BIXT)

    Mike Sheikh, Executive Vice President Business Development

    10:50 - 11:20

    Inspire Veterinary Partners, Inc. (NASDAQ:IVP)

    Kimball Carr, Chairman, President & CEO

    12:00 - 12:30

    BioLargo, Inc. (OTCQB:BLGO)

    Dennis Calvert, President / CEO

    1:10 - 1:40

    Nextech3D.ai, (OTCQX:NEXCF) (CSE:NTAR) (FSE: EP2)

    Evan Gappelberg, CEO

    1:45 - 2:15

    Sokoman Minerals Corp., (OTCQB:SICNF) (TSXV:SIC)

    Timothy Froude P. Geo. CEO, Pres & Director

    2:20 - 2:50

    Knightscope, Inc. (NASDAQ:KSCP) 

    William Santana Li  Chairman & CEO

    2:55 - 3:05

    Cyngn, Inc. (NASDAQ:CYN)

    Lior Tal, CEO & Director

    3:10 - 3:20

    Citizens, Inc. (NYSE:CIA)

    Gerald W. Shields, Vice Chairman / CEO, & Jeff Conklin, CFO

    3:25 - 3:35

    Ampio Pharmaceuticals, Inc. (NYSE:AMPE)

    Michael Martino, CEO & Director

    3:40 - 3:50

    Steppe Gold, Ltd. (OTCQX:STPGF) (TSX:STGO)

    Aneel Singh, Exec. VP & Director

    3:55 – 4:05

    Regen Biopharma, Inc. (OTC:RGBP)

    David Koos, President / CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    Presented on October 4, 2023:

    AGBA Group Holding Limited (NASDAQ:AGBA)

    Mr. Wing-Fai Ng, Group President of AGBA Group

    Loop Industries, Inc. (NASDAQ:LOOP)

    Kevin C. O'Dowd, VP Communications

    CoTec Holdings Corp. (OTCQB:CTHCF) (TSXV:CTH)

    Julian Treger, President / CEO

    ASP Isotopes, Inc. (NASDAQ:ASPI)

    Paul Elliot Mann, CEO

    Akari Therapeutics, plc (NASDAQ:AKTX)

    Rachelle Jacques, CEO

    FendX Technologies, Inc. (OTCQB:FDXTF) (CSE:FNDX)

    Carolyn Jane Myers, CEO

    NeuroSense Therapeutics, Ltd. (NASDAQ:NRSN)

    Alon Ben-Noon, Co-Founder, CEO & Director

    Rakovina Therapeutics Inc. (TSXV:RKV)

    Jeffrey Bacha, Executive Chairman & David Hyman, President

    Alpha Tau Medical, Inc. (NASDAQ:DRTS)

    Raphi Levy, CFO

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    David Dodd, Chairman, President / CEO

    Renforth Resources, Inc. (OTCQB:RFHRF) (CSE:RFR)

    Nicole Brewster, President & CEO

    NeuroMetrix, Inc. (NASDAQ:NURO)

    Dr. Shai Gozani, CEO & Thomas Higgins, CFO

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: Conference@EmergingGrowth.com 



    Primary Logo

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $AKTX
    $AMPE
    $ASPI

    CompanyDatePrice TargetRatingAnalyst
    Alpha Tau Medical Ltd.
    $DRTS
    5/28/2026$15.00Overweight
    Barclays
    Akari Therapeutics plc
    $AKTX
    4/8/2026Buy → Hold
    Maxim Group
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    More analyst ratings

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    SEC Filings

    View All

    SEC Form DEF 14A filed by Akari Therapeutics plc

    DEF 14A - Akari Therapeutics Plc (0001541157) (Filer)

    6/4/26 4:30:36 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by GeoVax Labs Inc.

    EFFECT - GeoVax Labs, Inc. (0000832489) (Filer)

    6/4/26 12:15:22 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Akari Therapeutics plc

    D - Akari Therapeutics Plc (0001541157) (Filer)

    6/3/26 5:00:17 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026

    Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing key themes emerging from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and Akari's positioning within the evolving ADC landscape. In the segment, Mr. Gaslightwala reflects

    6/4/26 9:30:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

    - Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape  - Collaboration elevates prostate cancer as a core strategic focus, backed by Tolmar's initial $15M manufacturing investment, $20M equity infusion at $11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical, regulatory and commercial milestones for the first indication - Agreement grants Tolmar exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer subject to additional payments - Alpha Tau to manufacture Alpha DaRT for Tolmar's commercialization,

    6/3/26 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

    - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of three prospective Phase I/II studies in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging median overall survival (mOS) across chemotherapy-naive, second-line, and heavily pretreated patient populations - - Patients treated with Alpha DaRT after 1st line chemotherapy reached median overall survival (mOS) of 11.2 and 11.1 months in metastatic and locally advanced disease, respectively, from the date of trial enrollment, compared to ~4 - 6 months for met

    6/1/26 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stenberg Jon bought $48,192 worth of Citizens (10,000 units at $4.82), increasing direct ownership by 3% to 327,574 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    5/26/26 10:28:12 AM ET
    $CIA
    Life Insurance
    Finance

    Director Hart Spencer bought $66,070 worth of shares (50,000 units at $1.32), increasing direct ownership by 14% to 410,370 units (SEC Form 4)

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    11/12/25 4:33:21 PM ET
    $LOOP
    Major Chemicals
    Industrials

    CEO Gaslightwala Abizer bought $19,540 worth of American Depositary Shares representing Ordinary Shares (21,000 units at $0.93), increasing direct ownership by 8% to 298,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    8/29/25 4:55:12 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Davis Jerry increased direct ownership by 2% to 74,985 units (SEC Form 4)

    4 - CITIZENS, INC. (0000024090) (Issuer)

    6/4/26 5:06:50 PM ET
    $CIA
    Life Insurance
    Finance

    Chief Financial Officer Levy Raphi sold $352,115 worth of Ordinary Shares (32,500 units at $10.83), decreasing direct ownership by 18% to 147,680 units (SEC Form 4)

    4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    6/4/26 2:29:30 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Mann Paul Elliot was granted 2,233,555 shares and sold $2,004,337 worth of shares (251,275 units at $7.98) as part of a pre-agreed trading plan, increasing direct ownership by 26% to 9,579,845 units (SEC Form 4) (withholding tax)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    6/3/26 9:45:38 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Alpha Tau with a new price target

    Barclays initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $15.00

    5/28/26 8:55:01 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Akari Therapeutics downgraded by Maxim Group

    Maxim Group downgraded Akari Therapeutics from Buy to Hold

    4/8/26 8:06:49 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Tau downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

    3/4/26 8:30:52 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Financials

    Live finance-specific insights

    View All

    Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

    - Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment - - One associated grade 3 serious adverse event (SAE) was observed, since resolved - - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months - - Conference call with principal investigator to be held today, Monday, May 11, 2026, at 8:30am ET - JERUSALEM, May 11, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or t

    5/11/26 7:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

    JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial. Conference Call and Webcast Details Date: Monday, May 11, 2026Time: 8:30am ETWeb Access: https://alpha-tau-interim-results-conference-call.open-exchange.net/

    5/8/26 9:10:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Cyngn Announces Date for First Quarter 2026 Financial Results

    MOUNTAIN VIEW, Calif., May 6, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) will announce its first quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 13, 2026, after the close of market. The financial results will be available on the Cyngn website under "News & Events" at https://investors.cyngn.com/.  The Company will not host an earnings call.About CyngnCyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges facing industrial orga

    5/6/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum Leap Energy Appoints Dr. Peter Fiske to Strategic Advisory Board

    DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Dr. Peter S. Fiske to QLE's Strategic Advisory Board (SAB). "QLE is intentionally building the leadership, advisory depth, and execution discipline required to scale throughout government and commercial nuclear energy markets," said Dr. Ryno Pretorius, Chief Executive Officer of QLE. "Dr. Fiske brings firsthand experience from the highest levels of government en

    5/6/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Quantum Leap Energy Appoints Nate Salpeter, Ph.D., a Key Opinion Leader in Fluid Dynamics and Energy Technology, as its Chief Technology Officer

    DALLAS, March 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Nate Salpeter, Ph.D. as its Chief Technology Officer. Dr. Salpeter is a recognized key opinion leader in the field of physics-constrained energy technology optimization, with more than 15 years of experience building computational frameworks, laser-based experimental methods, and first-of-kind engineering programs across nuclear energy and advanced thermal sys

    3/5/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care